We’d love to hear your feedback on this activity. It helps us to continually improve our products.
Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA
Prof. Michael Jordan is a professor of paediatrics at Cincinnati Children’s Hospital Medical Center (CCHMC) and the University of Cincinnati School of Medicine, OH, USA. He is also the scientific director of the CCHMC HLH Center of Excellence. read more
Prof. Jordan provides clinical care and consultation for patients with HLH and other immune conditions. He conducts clinical and laboratory research to improve the diagnosis and treatment of HLH, and is internationally known for his scientific and medical expertise related to HLH and other inborn immunoregulatory disorders.
He is the past president of the Histiocyte Society, and his scientific work provides the foundation for modern understanding of how HLH develops. His discoveries over the last two decades led to the development of treatments for patients with HLH. Prof. Jordan also directs the INTO-HLH Registry, which aims to help improve the diagnosis, treatment and outcomes for children and adults with HLH.
Prof. Michael Jordan discloses: Advisory board or panel fees from Sobi Inc. Consultancy fees from Vertex Pharmaceuticals (relationship terminated). Grants and research support from Bristol Myers Squibb and Sobi Inc.
UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA
Dr Kate Kernan is an assistant professor of critical care medicine at the Children’s Hospital of Pittsburgh of UPMC, PA, USA, and is a National Institute of Child Health and Human Development Pediatric Critical Care and Trauma Scientist Development Program Scholar. read more
Dr Kernan completed her paediatric residency at Washington University in St. Louis followed by fellowship training at the Children’s Hospital of Pittsburgh. She has been a scientist at the Safar Center for Resuscitation Research since 2021. In 2023, she was awarded a K23 through the National Institute of General Medical Sciences to facilitate development of her research portfolio. Dr Kernan’s research is focused on understanding how individual genetic variation contributes to critical illness susceptibility and outcomes. Dr Kernan’s work has shown that children with genetic variation related to primary immunodeficiencies are at high risk for bacterial infections, extreme inflammation and often require extracorporeal therapy. Additional studies of children with innate immune variants, particularly those related to complement disorders, show that these children share unique illness characteristics typical of disorders of complement activation such as atypical haemolytic uremic syndrome.
Dr Kate Kernan has no interests/relationships or affiliations to disclose in relation to this activity.
University of Florida Health, Gainesville, FL, USA
Dr Eric Gars is a clinical assistant professor in the Department of Pathology, Immunology and Laboratory Medicine at the University of Florida in Gainesville, FL, USA. read more
Dr Gars is board certified in anatomic pathology and haematopathology. His clinical interests include lymphoma, leukaemia and gynaecological cancer. He has published on diagnostic approaches for HLH.
Dr Eric Gars discloses: Grants and research support from Guided Therapeutics.
University of Colorado, Denver, CO, USA
Prof. Rob MacLaren is a professor in the Department of Clinical Pharmacy at the University of Colorado and clinical pharmacist in the medical intensive care unit (ICU) at the University of Colorado Hospital, Denver, CO, USA. read more
Prof. MacLaren completed his undergraduate degree in pharmacy at the University of British Columbia. He earned his D Pharm at the University of Utah and completed a critical care specialty residency at the University of Tennessee/Baptist Memorial Hospital in Memphis, TN.
Prof. MacLaren has over 150 peer-reviewed publications relating to the pharmacologic and nutritional therapies of critically ill patients and has secured over $800,000 in grant funding to support various research initiatives. His primary research areas include gastrointestinal disturbances of the critically ill, optimizing patient comfort in the ICU, and demonstrating the value of clinical pharmacy services. He has been an invited speaker at national and international meetings. He is also a fellow of the American College of Clinical Pharmacy and master of the Society of Critical Care Medicine.
Prof. Rob MacLaren has no interests/relationships or affiliations to disclose in relation to this activity.